Tatva Chintan Pharma Chem delivered robust consolidated Q2 FY26 results.

Revenue surged 48% year-on-year to ₹123.5 Cr, with Profit After Tax (PAT) dramatically increasing to ₹9.9 Cr from a previous loss.

For H1 FY26, revenue grew 27% year-on-year to ₹240.4 Cr, and PAT climbed 265% to ₹16.6 Cr.

Earnings per share also saw strong improvement.

Growth was notably strong in Structure Directing Agents (SDA), accounting for 48% of Q2 revenue.

The company's strategy emphasizes green chemistry processes like electrolysis for SDA production and developing continuous flow chemistry, backed by significant R&D investment.

Recent developments include the commencement of commercial production at its expanded Dahej SEZ facility and raising ₹200 Cr through a Qualified Institutional Placement in August 2023 to boost capacities.

Tatva Chintan maintains a strong position in niche specialty chemicals, benefiting from India's expanding footprint in the global chemical market, the 'China+1' strategy, and a growing demand for sustainable products.

Their diversified product portfolio, technical expertise, and high industry entry barriers are key strengths driving future growth.